NBIX - Neurocrine Biosciences - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NBIX is currently covered by 24 analysts with an average price target of $156.02. This is a potential upside of $27.79 (21.67%) from yesterday's end of day stock price of $128.23.

Neurocrine Biosciences's activity chart (see below) currently has 328 price targets and 318 ratings on display. The stock rating distribution of NBIX is 75.65% BUY and 24.35% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 76.62% with an average time for these price targets to be met of 268.32 days.

Highest price target for NBIX is $189, Lowest price target is $115, average price target is $163.88.

Most recent stock forecast was given by PAUL MATTEIS from STIFEL on 31-Jul-2025. First documented stock forecast 04-Feb-2015.

Currently out of the existing stock ratings of NBIX, 87 are a BUY (75.65%), 28 are a HOLD (24.35%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$174

$45.77 (35.69%)

$144

3 days ago
(31-Jul-2025)

19/20 (95%)

$45.77 (35.69%)

504

Buy

$158

$29.77 (23.22%)

$150

3 days ago
(31-Jul-2025)

7/13 (53.85%)

$29.77 (23.22%)

453

Buy

$141

$12.77 (9.96%)

$147

3 days ago
(31-Jul-2025)

11/13 (84.62%)

$12.77 (9.96%)

476

Buy

$144

$15.77 (12.30%)

$145

3 days ago
(31-Jul-2025)

17/22 (77.27%)

$15.77 (12.30%)

117

Buy

$175

$46.77 (36.47%)

$154

3 days ago
(31-Jul-2025)

13/17 (76.47%)

$46.77 (36.47%)

375

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NBIX (Neurocrine Biosciences) average time for price targets to be met?

On average it took 268.32 days on average for the stock forecasts to be realized with a an average price target met ratio 76.62

Which analyst has the current highest performing score on NBIX (Neurocrine Biosciences) with a proven track record?

DANIELLE BRILL

Which analyst has the most public recommendations on NBIX (Neurocrine Biosciences)?

Danielle Brill works at RAYMOND JAMES and has 7 price targets and 7 ratings on NBIX

Which analyst is the currently most bullish on NBIX (Neurocrine Biosciences)?

Jay Olson with highest potential upside - $90.77

Which analyst is the currently most reserved on NBIX (Neurocrine Biosciences)?

Thomas Wei with lowest potential downside - -$69.25

Neurocrine Biosciences in the News

Neurocrine (NBIX) Q2 Revenue Jumps 17%

Key Points Non-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. GAAP revenue reached $687.5 million for Q2 2025, beating expectations by $33.6 million and Revenue rose 16.5% year-over-year to $687.5 million. CRENESSITY launched with $53.2 million in first full-quarter sales, marking robust market uptake.These 10 stocks could...

Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales

Investing.com – Guggenheim raised its price target on Neurocrine Biosciences (NASDAQ:NBIX) to $175.00 from $165.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter earnings report. The $13.15 billion market cap company, which InvestingPro data shows has achieved a 21.73% revenue growth over the last twelve months, maintains a “GREAT” financial health score....
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?